Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the month of November 2019. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMR) and persons closely associated with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports specific share transaction details:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction 1 (Exercise): 137,040 shares exercised at £12.035 per share.
- Transaction 2 (Sale): 112,945 shares sold at £17.7588 per share to cover tax and exercise costs.
- Transaction 3 (Transfer): 24,095 shares transferred for £0.00 consideration.
Material Changes
The filing does not report material changes to the company's business operations or financial position compared to prior periods. It documents a discrete event involving the Chief Executive Officer's shareholding adjustments on October 31, 2019.
Management Commentary and Risks
There is no management commentary, forward-looking guidance, or discussion of risks and contingencies in this specific filing. The document is a regulatory disclosure of the following events:
- Ms. E. Walmsley (CEO): Exercised options granted in July 2010, sold a portion of the resulting shares on the London Stock Exchange to cover costs, and transferred the remainder to her spouse.
- Mr. David Owen (PCA of CEO): Received the transferred shares from Ms. Walmsley for nil consideration.
Investor Verification Checklist
- Verify the total number of shares retained by the CEO after the exercise, sale, and transfer.
- Confirm the tax implications of the sale price (£17.7588) versus the exercise price (£12.035).
- Check subsequent filings for any changes in the CEO's total beneficial ownership.
- Note that this filing contains no data on the company's overall financial performance for the period.